84.58
0.94 (1.12%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Nuvalent, Inc. | Bullish | Bullish |
Stockmoo Score
|
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 135.00 (Stifel, 59.61%) | Buy |
| Median | 100.00 (18.23%) | |
| Low | 99.00 (Wedbush, 17.05%) | Buy |
| Average | 113.20 (33.84%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 86.84 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 16 Sep 2024 | 132.00 (56.07%) | Buy | 87.45 |
| Stifel | 16 Sep 2024 | 135.00 (59.61%) | Buy | 87.45 |
| 10 Jul 2024 | 115.00 (35.97%) | Buy | 74.52 | |
| Wedbush | 09 Sep 2024 | 99.00 (17.05%) | Buy | 89.24 |
| JP Morgan | 04 Sep 2024 | 100.00 (18.23%) | Buy | 84.58 |
| Barclays | 29 Aug 2024 | 100.00 (18.23%) | Buy | 85.50 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MILLER DEBORAH ANN | - | 89.24 | -3,000 | -267,720 |
| NOCI DARLENE | - | 83.64 | -5,000 | -418,200 |
| Aggregate Net Quantity | -8,000 | |||
| Aggregate Net Value ($) | -685,920 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 86.44 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MILLER DEBORAH ANN | Officer | 09 Sep 2024 | Automatic sell (-) | 3,000 | 89.24 | 267,720 |
| MILLER DEBORAH ANN | Officer | 09 Sep 2024 | Option execute | 3,000 | - | - |
| NOCI DARLENE | Officer | 03 Sep 2024 | Automatic sell (-) | 5,000 | 83.64 | 418,200 |
| NOCI DARLENE | Officer | 03 Sep 2024 | Option execute | 5,000 | - | - |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |